Epithalon
Also called Epitalon
What to know about Epithalon
Epithalon, also called Epitalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly. It must be distinguished from epithalamin, a multi-component pineal extract used in older human publications.
- How it may work
- Laboratory reports propose effects on telomerase, gene expression, oxidative processes, and circadian signalling. These hypotheses lack a mature human evidence chain.
- What research found
- Frequently cited human longevity findings used epithalamin, not pure synthetic Epithalon. Small cell and animal studies cannot bridge that identity gap.
- What is not settled
- Reliable human pharmacokinetics, standardized product studies, and long-term surveillance for the synthetic tetrapeptide are lacking.
- Research and product status
- Epithalon has no licensed U.S. product. Claims should identify the exact material studied instead of combining extract and tetrapeptide evidence.
Research reference
- Research amount range
- 5–10 mg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- No human administration route established by this catalogue's evidence tier.
- Model accumulation timescale
- ~3 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- Human longevity claims often cite older work on epithalamin, an extract, rather than the synthetic tetrapeptide epithalon. That identity mismatch prevents a reliable time-to-result claim.
- When to assess
- No direct, well-controlled human outcome trial establishes when to reassess the synthetic tetrapeptide for sleep, ageing markers, lifespan, or other marketed goals.
- Conditions and limitations
- No dependable evidence establishes a required time of day, annual cycle, route, fasting state, or companion compound for the synthetic tetrapeptide.
- When to stop
- No validated target, course length, maintenance phase, or quit rule exists. Repeating calendar-based courses cannot be justified by studies of a different extract.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Key properties
- Formula
- C14H22N4O9
- Mol. weight
- 390.35 Da
- CAS
- 307297-39-8
- PubChem CID
- 219042
Sequence (one-letter)
AEDG
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Short tetrapeptide; little published human PK.
Circulating amounts trace to a single research group and to community write-ups rather than independently replicated trials, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Epithalon / pineal-peptide literature (Khavinson)Mostly Russian longevity research; human pharmacokinetic data is minimal.